December 6, 2017 at 9:00 P.M. EST - Recording Available
This program will provide an update of current standards of therapy for first- and second line treatment of extensive-stage small cell lung cancer (SCLC).
Monday, December 4, 2017 1:00PM EST / 11:00AM MST/ 7:00PM CET - Recording Available
This program will examine current treatment standards for stage III non-small cell lung cancer (NSCLC).
Wednesday November 15, 2017 12:00PM EST / 10:00AM MDT / 6:00PM CET - Recording Available
This webinar will review selected presentations made at the 2017 ASTRO Annual Meeting that address the evolving role of radiation therapy in the treatment of lung malignancies.
Thursday, November 9, 2017 at 9:00PM EST - Recording Available
The IASLC Atlas of PD-L1 Immunohistochemistry Testing in Lung Cancer is a new resource for understanding programmed cell death ligand-1 (PD-L1) immunohistochemistry (IHC) assays.
October 10, 2017 at 9:00PM EDT - Recording Available
Classification of NSCLC has been rapidly evolving, owing in large part to increased attention to histologic features and common molecular alterations.
October 9, 2017 at 7:00PM CEST - Recording Available
This webinar will highlight advances in the management of lung cancer reported during the recent European Society for Medical Oncology Congress ( ESMO 2017).
September 21, 2017 at 1:00 PM EST; September 21, 2017 at 6:00 PM EST - Recording Available
These live webinars are intended to help pathologists, scientists and physicians better understand the background, protocol and interpretation of results of ALK and ROS1 testing for NSCLC patients.
September 21, 2017 at 6:00PM HKT - Recording Available
This program will provide an updated view of the optimal management of ALK Positive Lung Cancer.
September 15, 2017 at 7:00PM CEST - Recording Available
In this webinar will discuss the optimal management of patients affected with brain metastases from non-small cell lung cancer (NSCLC).
September 6, 2017 at 9:00PM EDT - Recording Available
The National Lung Screening Trial provided clear evidence of a lung cancer mortality reduction in high-risk patients who undergo screening with low-dose CT.